The CNS disorder drug developer has launched with $76m from investors including Biogen, Bristol Myers Squibb and Pfizer Ventures.
US-based regenerative medicine developer Autobahn Therapeutics closed a $76m series B round on Tuesday featuring pharmaceutical companies Biogen, Bristol Myers Squibb and Pfizer, the latter through its Pfizer Ventures subsidiary.
Arch Venture Partners and Cowen Healthcare Investments co-led the round, which included BVF Partners, Invus, Section 32, Samsara BioCapital and Alexandria Venture Investments, the venture capital arm of real estate investment trust Alexandria Real Estate Equities.
Autobahn is developing treatments that target the body’s thyroid hormone in order to treat…
